US 12,201,761 B2
Peritoneal dialysis solution
Arduino Arduini, Arogno (CH); Mario Bonomini, Chieti (IT); Valentina Masola, Pernumia (IT); and Giovanni Gambaro, Scorzè (IT)
Assigned to COREQUEST Sagl, Lugano (CH)
Filed by COREQUEST Sagl, Lugano (CH)
Filed on Oct. 11, 2023, as Appl. No. 18/378,985.
Application 18/378,985 is a continuation of application No. 18/078,764, filed on Dec. 9, 2022, granted, now 11,964,087.
Application 18/078,764 is a continuation of application No. 17/318,001, filed on May 12, 2021, granted, now 11,779,692, issued on Oct. 10, 2023.
Claims priority of provisional application 63/026,936, filed on May 19, 2020.
Claims priority of application No. 20175357 (EP), filed on May 19, 2020.
Prior Publication US 2024/0042115 A1, Feb. 8, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 1/28 (2006.01); A61K 31/047 (2006.01); A61K 31/205 (2006.01); A61K 31/7004 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/40 (2006.01); A61P 7/08 (2006.01)
CPC A61M 1/287 (2013.01) [A61K 31/047 (2013.01); A61K 31/205 (2013.01); A61K 31/7004 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/40 (2013.01); A61P 7/08 (2018.01)] 13 Claims
 
1. A peritoneal dialysis solution comprising:
(a) a lactate buffered solution comprising xylitol at about 1.5%, L-carnitine at about 0.02% and polydextrin at about 4.0%, or
(b) a lactate buffered solution comprising glucose at about 1.5%, L-carnitine at about 0.02% and xylitol at about 2.0%.